Evidence receipt
OASIS 1: what the trial found
A plain-language summary of one study: who took part, what they got, what it was compared with, what happened in each group, its limits and who paid for it. One trial. Results are group averages, not a prediction for any one person.
Study: OASIS 1[1]
Does daily oral semaglutide 50 mg cause weight loss compared with placebo in adults with obesity or overweight and no diabetes?
- Who was in it
- 667 adults without type 2 diabetes, BMI 30 or more, or 27 or more with complications
- What they got
- Oral semaglutide increased to 50 mg once a day, with lifestyle intervention
- Compared with
- Placebo, with lifestyle intervention
- How long
- 68 weeks
- What happened
- Average weight change: −15.1% vs −2.4% on placebo. Stomach-related side effects: 80% vs 46%.
- Limits
- Tested 50 mg — not the 25 mg dose that was later approved
- People with diabetes were excluded
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Sources
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). The Lancet, August 26, 2023. https://pubmed.ncbi.nlm.nih.gov/37385278/ · DOI 10.1016/S0140-6736(23)01185-6 · PMID 37385278. Accessed November 2, 2026. Back to the text
Discussed in: Oral semaglutide (Rybelsus, Wegovy pill), explained
General information, not medical advice.